CN100496496C - Compound metformin glipidide preparation for treating diabetes type II, and its preparation method - Google Patents
Compound metformin glipidide preparation for treating diabetes type II, and its preparation method Download PDFInfo
- Publication number
- CN100496496C CN100496496C CNB2005102005848A CN200510200584A CN100496496C CN 100496496 C CN100496496 C CN 100496496C CN B2005102005848 A CNB2005102005848 A CN B2005102005848A CN 200510200584 A CN200510200584 A CN 200510200584A CN 100496496 C CN100496496 C CN 100496496C
- Authority
- CN
- China
- Prior art keywords
- metformin hydrochloride
- metformin
- cortex cinnamomi
- glipizide
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract description 104
- 150000001875 compounds Chemical class 0.000 title claims abstract description 4
- 238000002360 preparation method Methods 0.000 title claims description 48
- 229960003105 metformin Drugs 0.000 title claims description 27
- 206010012601 diabetes mellitus Diseases 0.000 title abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 86
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims abstract description 57
- 229960001381 glipizide Drugs 0.000 claims abstract description 57
- 239000003814 drug Substances 0.000 claims abstract description 32
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 96
- 229960004329 metformin hydrochloride Drugs 0.000 claims description 76
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 claims description 76
- 238000002156 mixing Methods 0.000 claims description 65
- 238000000605 extraction Methods 0.000 claims description 58
- 229920002472 Starch Polymers 0.000 claims description 56
- 235000019698 starch Nutrition 0.000 claims description 56
- 239000008107 starch Substances 0.000 claims description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 40
- 239000008187 granular material Substances 0.000 claims description 39
- 108010010803 Gelatin Proteins 0.000 claims description 38
- 239000008273 gelatin Substances 0.000 claims description 38
- 229920000159 gelatin Polymers 0.000 claims description 38
- 235000019322 gelatine Nutrition 0.000 claims description 38
- 235000011852 gelatine desserts Nutrition 0.000 claims description 38
- 238000001035 drying Methods 0.000 claims description 33
- 239000006187 pill Substances 0.000 claims description 31
- 239000000463 material Substances 0.000 claims description 30
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 30
- 238000004821 distillation Methods 0.000 claims description 29
- 239000000341 volatile oil Substances 0.000 claims description 29
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 26
- 238000013329 compounding Methods 0.000 claims description 25
- 239000003826 tablet Substances 0.000 claims description 25
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 23
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 23
- 239000011734 sodium Substances 0.000 claims description 23
- 229910052708 sodium Inorganic materials 0.000 claims description 23
- 239000007919 dispersible tablet Substances 0.000 claims description 21
- 239000008188 pellet Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 239000007901 soft capsule Substances 0.000 claims description 20
- 239000007779 soft material Substances 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 19
- 235000012424 soybean oil Nutrition 0.000 claims description 19
- 239000003549 soybean oil Substances 0.000 claims description 19
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 18
- 239000011248 coating agent Substances 0.000 claims description 18
- 238000000576 coating method Methods 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 18
- 239000003292 glue Substances 0.000 claims description 18
- 239000000600 sorbitol Substances 0.000 claims description 18
- 238000000465 moulding Methods 0.000 claims description 17
- 239000000758 substrate Substances 0.000 claims description 16
- 238000005469 granulation Methods 0.000 claims description 15
- 230000003179 granulation Effects 0.000 claims description 15
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 13
- 239000011812 mixed powder Substances 0.000 claims description 13
- 238000004513 sizing Methods 0.000 claims description 13
- 239000004408 titanium dioxide Substances 0.000 claims description 13
- 238000005096 rolling process Methods 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 238000012856 packing Methods 0.000 claims description 10
- 230000007246 mechanism Effects 0.000 claims description 8
- 239000002390 adhesive tape Substances 0.000 claims description 7
- 239000002826 coolant Substances 0.000 claims description 7
- -1 polyoxyethylene monostearate Polymers 0.000 claims description 7
- 239000002002 slurry Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 6
- 238000007664 blowing Methods 0.000 claims description 6
- 230000036760 body temperature Effects 0.000 claims description 6
- 229940008099 dimethicone Drugs 0.000 claims description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 6
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000007902 hard capsule Substances 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 6
- 238000010792 warming Methods 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 5
- 235000010357 aspartame Nutrition 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 239000006196 drop Substances 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 5
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000001238 wet grinding Methods 0.000 claims description 5
- 108010011485 Aspartame Proteins 0.000 claims description 4
- 239000000605 aspartame Substances 0.000 claims description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 229960003438 aspartame Drugs 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- 229960003511 macrogol Drugs 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 7
- 235000008499 Canella winterana Nutrition 0.000 abstract 1
- 244000080208 Canella winterana Species 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 229940017545 cinnamon bark Drugs 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 27
- 229940023488 pill Drugs 0.000 description 27
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 239000008103 glucose Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 239000002775 capsule Substances 0.000 description 15
- 102000004877 Insulin Human genes 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 12
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 235000010489 acacia gum Nutrition 0.000 description 7
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 229940123208 Biguanide Drugs 0.000 description 5
- 229940100389 Sulfonylurea Drugs 0.000 description 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 5
- 150000004283 biguanides Chemical class 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003605 opacifier Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000001610 euglycemic effect Effects 0.000 description 4
- 238000000703 high-speed centrifugation Methods 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
A compound medicine for treating diabetes B is prepared from flumamine hydrochloride, glipizide, the extract of cinnamon bark and auxiliary. Its preparing process is also disclosed.
Description
Technical field: the present invention is a kind of compounding metformin glipidide for the treatment of type 2 diabetes mellitus and preparation method thereof, belongs to the technical field of drug compound preparation.
Technical background: type 2 diabetes mellitus be a kind of be the endocrine metabolism disease of feature with sugar, fat and protein metabolism disorder.The topmost performance of diabetes is exactly a hyperglycemia.Hyperglycemia is meant that fasting glucose is higher than upper limits of normal 7.3mmol/L (130mg/dl), and blood glucose is higher than renal glucose threshold value 9.0mmol/L (160mg/dl), glucose in urine then occurs.In recent years, along with the raising of living standards of the people, the prevalence of diabetes is in continuous rising, and it is the sickness rate height not only, and complication is many, and the generation of complication is to cause the diabetes patient to be disabled even dead major reason.Diabetes have become a big arch-criminal who threatens human health.IDF has the loud slogan of sentence " to reduce the cost because of diabetes ignorant is paid ".Medicine is correctly selected in early discovery, and the science treatment is the key point of curing diabetes.
The medicine of treatment type 2 diabetes mellitus comprises sulfonylurea insulin secretion stimulators, biguanides qualifying row ketone euglycemic agent at present.More insulin reduces plasma glucose levels thereby the sulfonylurea insulin secretion stimulators can make islets of langerhans b-emiocytosis.Biguanides blood sugar reducing function mechanism extensively.Many researchers being arranged with sulfonylureas and biguanides use in conjunction, is Chinese patent application invention disclosed content such as 200410032013 and 02108983 as application number, has obtained hypoglycemic effect preferably.But the morbidity true cause of type 2 diabetes mellitus mainly is the generation of insulin resistant in the body.So-called insulin resistant is sensitivity and reactive reduce of insulin to the regulating action of blood glucose, lipid and Proteometabolism etc.So since glitazone euglycemic agent listing, aspect the generation of the blood sugar lowering of diabetic and its complication of inhibition, brought into play bigger effect.Influenced promoting the use of of it greatly but regrettably the glitazone euglycemic agent is proved to be liver toxicity afterwards.So the eye of researcher turns to the research of Chinese medicine euglycemic agent.The present invention is directed to existing blood sugar lowering Western medicine and do corresponding improvement, add Cortex Cinnamomi extract, when guaranteeing safety of medicine, onset time obviously shortens, and hypoglycemic effect also significantly strengthens.
Summary of the invention: the present invention is according to the reason and the Therapeutic Method of onset diabetes, proposition adds the Cortex Cinnamomi that is proved to be insulin-sensitizing activity on the basis of sulfonylureas and biguanides use in conjunction, change that drug regimen in the past takes stopgap measures merely and the situation of not effecting a permanent cure.Therefore the objective of the invention is to be to provide the compositions of the Cortex Cinnamomi extract of a kind of sulfonylureas glipizide, biguanides metformin and tool insulin-sensitizing activity, and the preparation that contains this compositions, and the method for preparing these preparations.Micropill provided by the invention, dispersible tablet, disintegrative are good, and the bioavailability height is particularly suitable for infant, old people and swallow tablet or the inconvenient patient of capsule take; Soft capsule preparation provided by the invention forms drug blockage in soft gel coat, solved medicine and met damp and hot problem of unstable, can also cover adverse drug taste, abnormal smells from the patient, can play the effect that increases stability, improves bioavailability; Granule good mouthfeel provided by the invention does not need disintegrate, absorbs soon taking convenience.
The present invention constitutes like this: calculate according to composition by weight, it is with 62～188 parts of metformin hydrochloride, 1～4 part of glipizide, 75～225 parts of Cortex Cinnamomi extracts, right amount of auxiliary materials is made in addition: tablet, dispersible tablet, buccal tablet, chewable tablet, fuse, effervescent tablet, slow releasing tablet, controlled release tablet, enteric coatel tablets, capsule, soft capsule, slow releasing capsule, controlled release capsule, enteric coated capsule, paste, pill, comprise drop pill, sugar pill, piller, micropill, concentrated pill, the watered pill, syrup, aerosol, powder spray, spray, oral solution, oral suspensions, Orally taken emulsion, powder, suppository, injection, extractum, soft extract reaches pharmaceutically acceptable dosage form.
A kind of compounding metformin glipidide for the treatment of the type 2 diabetes mellitus disease provided by the invention, its better prescription is: calculate according to composition by weight, it is with 90～160 parts of metformin hydrochloride, 2～3 parts of glipizide, 100～200 parts of Cortex Cinnamomi extracts, and in addition right amount of auxiliary materials is made into tablet, dispersible tablet, hard capsule, soft capsule, granule, powder, pellet, drop pill or oral liquid.
A kind of compounding metformin glipidide for the treatment of the type 2 diabetes mellitus disease provided by the invention, its optimum prescription is: calculate according to composition by weight, it is with 125 parts of metformin hydrochloride, 2.5 parts of glipizide, 150 parts of Cortex Cinnamomi extracts, and in addition right amount of auxiliary materials is made into tablet, dispersible tablet, hard capsule, soft capsule, granule, powder, pellet, drop pill or oral liquid.
Cortex Cinnamomi extract described in the present invention is such preparation: get cinnamomic dry branch, leaf vapor distillation extraction method extraction 2～4 times, each 1～3 hour, merge volatile oil, when being 20 ℃, temperature measures relative density, its relative density is 1.0～1.1, promptly.
Granule in a kind of compounding metformin glipidide for the treatment of the type 2 diabetes mellitus disease provided by the invention prepares like this: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract according to given composition by weight, the starch that adds the 40%-60% of metformin hydrochloride weight, the dextrin of the 40%-60% of metformin hydrochloride weight, mixing, ethanol system wet granular with 10～30%, drying, granulate, packing, promptly.
Dispersible tablet in a kind of compounding metformin glipidide for the treatment of the type 2 diabetes mellitus disease provided by the invention prepares like this: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract, mixing according to given composition by weight; Other gets the low-substituted hydroxypropyl cellulose of the 15%-25% of metformin hydrochloride weight, the carboxymethyl starch sodium of the 10%-20% of metformin hydrochloride weight, mixing, get 3/5 with above-mentioned mixed powder mix homogeneously, make binding agent with 5～15% starch slurry, 40 order system material, granulate, mixed powder and 0.5～1% part of magnesium stearate of adding residue 2/5 low-substituted hydroxypropyl cellulose and carboxymethyl starch sodium are added in the granule that makes, mixing, tabletting, promptly.
Pellet in a kind of compounding metformin glipidide for the treatment of the type 2 diabetes mellitus disease provided by the invention prepares like this: get metformin hydrochloride according to given composition by weight, glipizide, Cortex Cinnamomi extract, the starch that adds the 20%-30% of metformin hydrochloride weight, mixing, with 20～30% ethanol and 1.2～1.5% soybean oil system soft materials, the soft material that makes micropill mechanism ball, wet feed pushed the 0.8mm sieve aperture, the wet grain of strip cuts off round as a ball, 50～60 ℃ of drying and mouldings, cross 16～20 mesh sieves and select ball or spray drying, wet-milling granulation molding, mould placed add the great achievement ball in the coating pan, medicated powder: water is 1:1.2～1.5, the coating pan rotating speed is 35～45r/min, capping selects ball, promptly.
Soft capsule in a kind of compounding metformin glipidide for the treatment of the type 2 diabetes mellitus disease provided by the invention prepares like this: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract according to given composition by weight, the PEG400 that adds the 5%-15% of metformin hydrochloride weight, the sorbitol of the 10%-20% of metformin hydrochloride weight, mixing; Press medication amount: substrate amount=1:1.2～1.5 add soybean oils, mixing; The prescription of rubber is a gelatin: glycerol: water: titanium dioxide=100:45:100:2, batchingization adhesive tape part is: weigh batching, in the inputization glue jar, merceration is warming up to 65 ± 5 ℃ gradually after 30～60 minutes, stirred 2～4 hours and simultaneously evacuation remove bubble, treat evenly back blowing of sizing material, incapsulate after the filtration in the sizing material bucket of machine; The debugging pellet press, 65 ± 5 ℃ of gelatin box temperature controls, mould rotating speed 1.0～3.0 is rolled in 45 ± 5 ℃ of sprinkler body temperature controls, rubber thickness 0.7～0.8mm, 18～25 ℃ of indoor temperatures, relative humidity is less than 40%, pelleting; The dry typing drying of rolling that adopts combined with two steps of tray dried, dry 1～3 hour of the typing of rolling, and 25 ± 5 ℃ of baking temperatures, dry relative humidity should be lower than 40%, and drying time is at 24～48 hours, promptly.
Drop pill in a kind of compounding metformin glipidide for the treatment of the type 2 diabetes mellitus disease provided by the invention prepares like this: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract according to given composition by weight, get the said mixture portion, two parts of Macrogol 4000s, polyoxyethylene monostearate S-40 portion, mix homogeneously, fuse in the water-bath, stir evenly, drip and in dimethicone, to become ball, drip apart from 3～7cm, drip footpath 2.5mm/2mm, mix 80 ± 5 ℃ of ointment temperature, liquid coolant height 70 ± 5cm, promptly.
Tablet in a kind of compounding metformin glipidide for the treatment of the type 2 diabetes mellitus disease provided by the invention prepares like this: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract according to given composition by weight, the starch that adds the 15%-25% of metformin hydrochloride weight, the carboxymethyl starch sodium of the 10%-20% of metformin hydrochloride weight, mixing, with 10～50% alcohol granulations, dry, granulate, add 1～5% part carboxymethyl starch sodium and 0.5～1% part magnesium stearate, mixing, tabletting, coating, promptly.
Oral liquid in a kind of compounding metformin glipidide for the treatment of the type 2 diabetes mellitus disease provided by the invention prepares like this: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract according to given composition by weight, mixing, add distilled water, 2～5% parts of aspartames, sterilization, promptly.
Powder in a kind of compounding metformin glipidide for the treatment of the type 2 diabetes mellitus disease provided by the invention prepares like this: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract according to given composition by weight, the starch that adds the 20%-30% of metformin hydrochloride weight, mixing, drying and crushing, sieve, divided dose, packing, promptly.
Capsule in a kind of compounding metformin glipidide for the treatment of the type 2 diabetes mellitus disease provided by the invention prepares like this: get metformin hydrochloride, glipizide and Cortex Cinnamomi extract according to given composition by weight, the starch that adds the 15%-40% of metformin hydrochloride weight, mixing, use 80% alcohol granulation, filling, promptly.
A kind of compounding metformin glipidide for the treatment of the type 2 diabetes mellitus disease provided by the invention mainly is made up of metformin hydrochloride, glipizide, Cortex Cinnamomi extract.Metformin hydrochloride is not by stimulating beta Cell of islet to increase concentration of insulin, but directly act on sugared metabolic process, promote the anerobic glycolysis of sugar, increase muscle, peripheral tissues such as fat are to the picked-up and the utilization of glucose, thereby protect beta Cell of islet function in damaged condition to avoid further infringement, the long-term control that helps diabetes, can reduce type 2 diabetes mellitus patient empty stomach and postprandial hyperglycemia, the HbAlc 1%-2% that can descend, its hypoglycemic mechanism is: 1. increase the sensitivity of surrounding tissue to insulin, increase the glucose utilization of insulin-mediated; 2. increase of the utilization of noninsulin dependent tissue, as brain, hemocyte, renal medulla, intestinal, skin etc. to glucose.3. the inhibition gluconeogenesis function of liver reduces glycogen output.4. suppress intestinal wall cellular uptake glucose.5. suppress the biosynthesis and the storage of cholesterol, reduce blood triglyceride, total cholesterol level.Glipizide is a second filial generation sulphanylureas oral hypoglycemic, mainly acts on beta Cell of islet, promotes the endogenous insulin secretion; Suppress the hepatic glycogen decomposition and promote that muscle utilizes glucose.In addition, also may change the reactivity of insulin target tissue, strengthen insulin action by the outer effect of pancreas to insulin.
Micropill compared with prior art of the present invention: disintegrative is good, the bioavailability height, and zest is little, is particularly suitable for the old people and swallow tablet or the inconvenient patient of capsule take; Medicine tablet formulation provided by the invention, the mode of taking is more, can swallow, buccal and sucking take, it is convenient to use more than other oral solid formulation, simultaneously, this medicine is met water can rapid disintegrate form homodisperse aqueous solution in 3 minutes, solved the not high problem of effective ingredient bioavailability; Soft capsule of the present invention is that drug blockage is formed in soft gel coat, has solved medicine and has met damp and hot problem of unstable, can also cover adverse drug taste, abnormal smells from the patient, plays the effect that increases stability, improves bioavailability; Granule provided by the invention, good mouthfeel absorbs soon the bioavailability height simultaneously; Tablet of the present invention, its molding is better, and disintegrative is good, the bioavailability height.
The applicant finds in the process of development granule, granule enters in the body with solution state, compare with oral solid formulation, reduced disintegrating procedue in the body, help the absorption of this product, shortened onset time greatly, the inventor herein intends by adding correctives and preferred supplementary product kind, because consider among the crowd of being suitable for to have diabetics, and the sugar-free granule fully of drawing up, as correctives, whole supplementary product consumption is reduced with high-potency sweetener significantly.
The applicant finds during dispersible tablet in development, and pharmacopeia regulation dispersible tablet must disintegrate fully in the 3min in 19 ℃～21 ℃ water, and suspension ability, bioavailability, dispersed homogeneous degree etc. are also had higher requirements.The diameter of micropill is less than 2.5mm, and class is in particle properties, the bioavailability height.
The applicant finds in the process of development drop pill, substrate polyethylene glycols commonly used is that esterification forms, be the surface-active water-soluble base of a kind of tool (fusing point is 46～51 ℃), dissolubility to insoluble drug is not good, we add S-40 change polyethylene glycols itself and do not have close ester structure and surface-active character, help the absorption of medicine, if but the consumption of S-40 is too high, and can cause product to draw moist enhancing.
Experimental example 1: Study on Forming
(1) dispersible tablet Study on Forming
Dispersible tablet meet water rapidly disintegrate form the water dispersion tablet of uniform sticky suspension, it is poor to have solved disintegrative, stripping is shortcoming slowly, and the dispersible tablet that the applicant makes is disintegrate fully in the 3min in 19 ℃ of-21 ℃ of water, and suspension ability is good, bioavailability is high, dispersed homogeneous degree.
1. adjuvant screening
Prescription low-substituted hydroxypropyl cellulose starch slurry (%) disintegration time/s
+ carboxymethyl starch sodium
Add in adding
1 9 36 3 4.1
2 27 18 8 2.1
3 18 27 10 2.8
4 36 9 12 2.8
5 45 0 15 2.9
6 0 45 18 4.9
2. check disintegration
Adopting changes the basket method, and lift disintegration tester, tablet are got 6, observes the situation by screen cloth.Percent of pass height then disintegrative is good, more pleasant bulk absorption.
Disintegration (s)
Group 123456
1 batch 12 13 13 11 11 13 in tablet of the present invention
2 batches 14 11 13 10 11 12 in tablet of the present invention
3 batches 11 9 10 11 13 12 in tablet of the present invention
The result shows, get low-substituted hydroxypropyl cellulose and carboxymethyl starch sodium mixing, get 3/5 with the mixed powder mix homogeneously, starch slurry with 8% is made binding agent, 40 order system material, granulate, the mixed powder that remains 2/5 low-substituted hydroxypropyl cellulose and carboxymethyl starch sodium mixing is added in the particle that makes, tabletting, and the dispersible tablet product that obtains is easy to disintegrate.
(2) pill moulding process
Research micropill diameter is less than 2.5mm, and class is in particle properties, the bioavailability height, and the applicant is when development product micropill of the present invention, and the micropill manufacturing technology and the adjuvant that adopt the applicant's screening to obtain make product be easy to disintegrate, and the bioavailability height is well-behaved.
1, extrudes-the spheronization pill
The system soft material is got mixed powder and starch, soybean oil and ethanol are made soft material with wet granulation process in right amount, makes it to reach to hold agglomeratingly, and that pinches can loose, standby.Research emphasis concentration of alcohol and soybean oil consumption influence pill, and experimental result sees Table.
Concentration of alcohol is investigated
| Tested number | Concentration of alcohol | System soft material situation | |
| 1 | 40～50 | % ethanol | Soft material easily bonds |
| 2 | 20～30 | % ethanol | Soft material is moderate |
| 3 | 10～20 | % ethanol | Soft material viscosity |
The soybean oil consumption is investigated
| Tested number | The soybean oil consumption | The pill situation |
| 1 | 20～30% ethanol, 0.5～1.0% soybean oil | Soft material viscosity is not enough, can't pill |
| 2 | 20～30% ethanol, 1.2～1.5% soybean oils | Soft material is moderate, suitable pill |
| 3 | 20～30% ethanol, 1.6～2.5% soybean oils | Soft material easily bonds, the pill difficulty |
The result as seen, it is more satisfactory to adopt 20～30% ethanol, 1.2～1.5% soybean oils to be that adhesive is granulated, otherwise is difficult to molding.
Soft material that pill makes is with micropill mechanism ball, and wet feed pushed the 0.8mm sieve aperture, and the wet grain of strip cuts off round as a ball, and 50～60 ℃ of drying and mouldings are crossed 16～20 mesh sieves and selected ball.
2, general method for making pill
Because the extruding that the humidification of water and coating pan rotate makes medicated powder be bonded into ball.General when making ball, water spray is fast and to add medicated powder speed slow, causes that it is bonding closely the time that then prolongs into ball, makes dry back hard, is unfavorable for the infiltration of moisture and influences molten loosing and the absorbing of medicine.
| Numbering | Coating pan rotating speed (r/min) | The molten diffusing time (min) | Mouldability |
| 1 | 20～30 | 6.93 | Relatively poor |
| 2 | 35～45 | 7.12 | Better |
| 3 | 50～65 | 12.35 | Harder |
| 4 | 70～85 | 14.38 | Hard |
| 5 | 90～100 | 15.49 | Hard |
The result shows that it is optimum that the coating pan rotating speed is selected 35～45r/min for use.
(4) soft capsule Study on Forming
Soft capsule disintegrate in gastrointestinal tract is fast, and after softgel shell broke, medicine disperseed rapidly, so the drug release stripping is fast, produce effects is rapid, the bioavailability height; Semi-transparent soft capsule can protect medicine not to be subjected to the effect of oxygen, light in dampness and the air with packaging material preferably, thereby improves the stability of labile element; So capsular stability and moulding process are very crucial technology.
A. supplementary product kind and consumption are selected:
1. disperse medium (or claiming substrate) is chosen in fill material and substrate energy mix homogeneously, and under the prerequisite of unobstructed defeated material of energy and pelleting, reduces substrates quantity as far as possible.By test of many times, determine medication amount (g): be advisable in substrate amount (g)=1:1.2～1.5, experimental result sees Table.
Substrates quantity is investigated
Medication amount (g): substrate amount (g) 1: 0.5～1 1: 1.2～1.5 1: 1.6～2.5
Big, the mobile difference viscosity of quality of liquid medicine viscosity, all good differences in viscosity of flowability are mobile big
2. capsule shells prescription screening according to the form below proportion scale is prepared burden, put into the 500ml bottle,suction, 65 ± 5 ℃ of water-baths are dissolved, automatic stirringization glue, the while evacuation, about vacuum 0.04～0.095Mpa, insulation was placed 1～2 hour after 2～4 hours, filtered glue, get a part of glue and measure viscosity and other performance, part glue evenly is paved into skim (smear below earlier one deck liquid paraffin) on iron plate, be positioned over to observe the rubber performance next day and judge again, with the investigation result of each pointer by good to poorly using " +++" successively, " ++ ", "+",, "-" expression the results are shown in Table.
Rubber batching The selection result
Dispensing viscosity flexibility flexibility elasticity toughness characteristics overall merit
(mpa·s)
1. gelatin: glycerol: water 3.62---+crisp, poor firmly
(100g:35g:100g)
2. gelatin: glycerol: water 3.32++ ++ ++ tough, film property is fine
(100g:45g:100g)
3. gelatin: glycerol: water 3.59++ ++ good springiness is general
(100g:55g:100g)
4. gelatin: glycerol: water 3.73 ++ +++good springiness, viscosity are fine greatly
(100g:45g:80g)
5. gelatin: glycerol: water 3.11 ++++-too soft poor
(100g:45g:120g)
6. gelatin: glycerol: sorbitol: water 3.43---+-tough better
(100g:35g:5g:100g)
7. gelatin: glycerol: sorbitol: water 3.46+++to pierce through performance good fine
(100g:35g:10g:100g)
8. gelatin: glycerol: sorbitol: water 3.52 ++++ tough better
(100g:45g:5g:100g)
9. gelatin: glycerol: sorbitol: water 3.47 +++-soft general
(100g:45g:10g:100g)
10. gelatin: glycerol: sorbitol: water 3.62++ ++ tough better
(100g:25g:10g:100g)
11. gelatin: glycerol: sorbitol: water 3.57++++to pierce through performance good fine
(100g:35g:20g:100g)
12. gelatin: glycerol: sorbitol: water 3.36 ++ +++0.5mm is better following
(100g:55g:5g:90g) rubber is easily broken
13. gelatin: glycerol: sorbitol: glue liquid is too thick, can't change glue
(84g:28g:28g:20g)
14. gelatin: arabic gum: 3.57---+color ash partially is poor
Glycerol: water
(100g:25g:35g:100g)
15. gelatin: arabic gum: 3.51-++ crisp poor
Glycerol: water
(85g:15g:45g:100g)
16. gelatin: arabic gum: 3.39++ ++ 0.2～0.8mm rubber
Glycerol: sorbitol: the water tearing strength is fine greatly
(85g:15g:60g:10g:60g)
17. gelatin: arabic gum: 3.68+---crisp poor
Sorbitol: glycerol: water
(50g:150g:10g:60g:55g)
18. gelatin: arabic gum: 3.52+++crisp general
Glycerol: sorbitol: the water color is ash partially
(85g:15g:45g:10g:110g)
19. gelatin: arabic gum: 3.38+++below the 0.85mm
Glycerol: sorbitol: glue skin poor flexibility is general
(85g:15g:60g:10g:90g)
20. gelatin: arabic gum: 3.35+-+ash is general partially for color
Glycerol: sorbitol: water
(100g:25g45g:5g:100g)
Through above screening, overall merit is considered the characteristics of fill material, and selecting prescription 2 is gelatin 100: glycerol 45: water 100.
3. opacifier is selected
The transparent adhesive tape softgel shell easily causes instability, so need to add a certain amount of opacifier.Select titanium dioxide (titanium dioxide) to make opacifier through investigation and can reach effective shaded effect, and steady quality, not with rubber cement and fill material generation chemical change.Its consumption is through investigating with gelatin: glycerol: water: titanium dioxide=100: 45: 100: 2 are advisable, and little to the rubber quality influence, the results are shown in Table.
The opacifier consumption is selected
Usage ratio rubber transparency rubber cement viscosity (MpaS) overall merit
Gelatin: glycerol: water: translucent 3.12 consumptions of titanium dioxide are not enough
(100g:45g:100g:0.5g)
Gelatin: glycerol: water: translucent 3.19 consumptions of titanium dioxide are not enough
(100g:45g:100g:1g)
Gelatin: glycerol: water: the translucent 3..36 of titanium dioxide is good
(100g:45g:100g:2g)
Gelatin: glycerol: water: opaque 3.52 viscosity of titanium dioxide are bigger
(100g:45g:100g:3g)
Quality is more stable after adding opacifier in the capsule shells prescription.
B. molding technological condition is investigated
1. grinding particle size is investigated
Mixed powder is pulverized, crossed 60 orders, 80 orders, 100 orders, 120 mesh sieves respectively, press mixed powder: substrate=1: 1.2 is even through the colloid mill mill, and observation mixing situation the results are shown in Table.
Grinding particle size is investigated
Granularity 60 orders 80 orders 100 orders 120 orders
The mixing situation can not mixing, can mixing, can mixing, and can mixing,
High speed centrifugation high speed centrifugation high speed centrifugation high speed centrifugation
(10000/min) (10000/min) (10000/min) (10000/min)
The not stratified 30min of the not stratified 30min of 30min layering 30min is not stratified
As seen from the above table, pulverized 80 orders, it is 80 orders that just energy mixing, so selection is pulverized the order number.
2. fill material combined experiments chamber is got mixed powder and pulverized 80 mesh sieves, presses extractum: substrate=1: 1.2～1.5 add soybean oil, use the colloid mill mixing, and evacuation removes bubble, and is standby.
3. the investigation of batchingization glue is a gelatin by aforementioned preferred prescription: glycerol: water: titanium dioxide=100: 45: 100: 2 weigh batchings with different temperatures glue, the results are shown in Table.
Changing the glue temperature investigates
Temperature (℃) change glue time (H) rubber quality
40～50 1～1.5 is general
50～60 1.5～2 is better
60～70 2～3 is good
70～80 3～4 is good
80～90 4～5 is harder
By the table prompting, it is the most suitable with 60～70 ℃ to change the glue temperature.So batchingization adhesive tape part is: weigh batching, in the inputizations glue jar, merceration is warming up to 65 ± 5 ℃ gradually after 30～60 minutes, stirs 2～4 hours also the while evacuation except that bubble, treat sizing material even after blowing, incapsulate after the filtration in the sizing material bucket of machine.
4. pelleting: the sizing material bucket and the spice bucket of room temperature of insulation are delivered to the capsule machine top, be connected, debug pellet press with machine, 65 ± 5 ℃ of gelatin box temperature controls, mould rotating speed 1.0～3.0 is rolled in 45 ± 5 ℃ of sprinkler body temperature controls, rubber thickness 0.7 ± 0.8mm, 18～25 ℃ of indoor temperatures, relative humidity is less than 40%.Treat that it is 300 ± 25mg/ grain that ball content loading amount is regulated in pellet press debugging back.Survey loading amount once every half an hour in the pelleting process.
5. dry: the dry soft capsule through pellet press extrusions of typing is in conveyer belt is delivered to rotating cage, and rotating cage is blown a cold wind over while rotating, rotates about 2 hours of the drying of finalizing the design.Tray dried soft gelatin capsule of cold air drying in rotating cage is contained in clean rustless steel charging tray splendid attire, moves to about 22 ℃ of temperature, and airing is 1～3 hour in the hothouse of relative humidity below 40%, and constantly stirs, and surveys capsule moisture and is being dry suiting below 10%.The drying lime light: the dry typing drying of rolling that adopts combined with two steps of tray dried, and the typing of rolling is dry is advisable with two hours through investigation, and overlong time is then rough; Baking temperature is advisable about investigating with 25 ± 5, and it is long that it's low drying time is past temperature, though increase in temperature can shorten drying time, easily produces Testudinis to capsule surface and splits; Dry relative humidity should be lower than 40% through investigating, otherwise is difficult for dry; Got final product below 10% with control moisture drying time about 24～48 hours.
(5) drop pill moulding process
The fusion situation of substrate and principal agent relatively
The result shows, the drop pill stripping that composite interstitial substance makes is very fast, because the esterification of polyethylene glycols substrate forms, it is a kind of surface-active water-soluble base (fusing point is 46～51 ℃) that has, S-40 has changed polyethylene glycols itself and has not had close ester structure and surface-active character, improve the dissolubility of insoluble drug, help the absorption of medicine.
The selection of 2. dripping distance, a speed, temperature is dripped distance, is dripped selection fast, temperature
The interior external diameter of drip is fixed as 4.1～6.1.Estimate pointer: the heavy qualification rate of ball is by mass discrepancy requirement of Pharmacopoeia of the People's Republic of China version in 2005: meet ± 7.5% within.
Group temperature/heavy qualification rate/the % of a ℃ distance/cm liquid coolant height/cm ball
1 90 4 50 78.3
2 90 5 60 86.4
3 90 8 70 82.0
4 80 4 60 91.3
5 80 5 70 95.2
6 80 8 50 90.0
7 70 4 70 91.7
8 70 5 50 89.1
9 70 8 60 85.2
The result shows, the optimum condition of preparation drop pill of the present invention: drip to become ball in dimethicone, drip apart from 3～7cm drip footpath 2.5mm/2mm, mix 80 ± 5 ℃ of ointment temperature, liquid coolant height 70 ± 5cm.
Experimental example 2 pharmacological testings
The inductive blood glucose in diabetic mice value test of alloxan Alloxan
Kunming mouse, body weight 20-22g, fasting 24h, lumbar injection Alloxan200mg/kg, once a day, fasting 10h behind the 72h, venous sinus get blood centrifuging and taking determination of serum blood glucose value, choose blood glucose value and experimentize the above person of 11.1mol/L.The difference of each treated animal average blood sugar value is not more than 0.5mol/L during grouping.Mice is divided into 5 groups, i.e. negative control group, positive controls (blood sugar lowering is happy), low dose group of the present invention, middle dosage group and high dose group.Negative control group is irritated the stomach normal saline, and positive controls is irritated 50mg/kg, and low dose group of the present invention is irritated stomach extract 200mg/kg, and middle dosage group is irritated stomach extract 400mg/kg, and high dose group is irritated stomach extract 600mg/kg.Successive administration 10d, fasting 10h after the last administration, the eye socket venous sinus is got blood, and centrifuging and taking serum is pressed the determination of glucose oxidase blood sugar level, the results are shown in Table.
The present invention is to the influence of the inductive blood glucose in diabetic mice value of Alloxan
Group dosage (mg/kg) N blood glucose value (mmol/L)
Negative control group 7 24.53 ± 1.34
Positive controls 50 8 16.12 ± 3.12*
Low dose group 200 7 17.53 ± 4.21* of the present invention
Dosage group 400 7 14.26 ± 2.35* among the present invention
High dose group 600 8 13.44 ± 3.26* of the present invention
*P<0.01
No matter the present invention is prevention administration or treatment administration, gastric infusion all can obviously suppress the rising of alloxan induced mice blood glucose, obviously descend with matched group comparison blood glucose, show that the present invention can weaken alloxan to the damage of beta Cell of islet or improve the function of damaged β emiocytosis insulin.Carbohydrate tolerance test shows that the present invention can obviously suppress the rising of blood glucose, makes glucose stimulate the increased functionality of beta Cell of islet excreting insulin.
Concrete embodiment
Embodiments of the invention 1: the preparation of granule
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.07, gets Cortex Cinnamomi extract 75g, and is standby; Get metformin hydrochloride 62g, glipizide 1g, starch 24.8g, dextrin 24.8g, add Cortex Cinnamomi extract 75g, mix homogeneously, the ethanol system wet granular with 10%, drying, granulate, packing promptly gets granule.Oral, three times on the one, each 2 parcels.
Embodiments of the invention 2: the preparation of granule
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.07, gets Cortex Cinnamomi extract 75g, and is standby; Get metformin hydrochloride 62g, glipizide 1g, starch 37.2g, dextrin 37.2g, add Cortex Cinnamomi extract 75g, mix homogeneously, the ethanol system wet granular with 30%, drying, granulate, packing promptly gets granule.
Embodiments of the invention 3: the preparation of granule
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.07, gets Cortex Cinnamomi extract 225g, and is standby; Get metformin hydrochloride 90g, glipizide 2g, starch 45g, dextrin 45g, add Cortex Cinnamomi extract 225g, mix homogeneously, the ethanol system wet granular with 20%, drying, granulate, packing promptly gets granule.
Embodiments of the invention 4: the preparation of dispersible tablet
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.06, gets Cortex Cinnamomi extract 100g, and is standby; Get low-substituted hydroxypropyl cellulose 13.5g, carboxymethyl starch sodium 9g, mixing, get 3/5 with metformin hydrochloride 90g, glipizide 2g, Cortex Cinnamomi extract 100g, mix homogeneously is made binding agent with 5% starch slurry, 40 order system material, granulate, the mixed powder, the 1g magnesium stearate that remain 2/5 low-substituted hydroxypropyl cellulose and carboxymethyl starch sodium are added in the granule that makes, mixing, tabletting promptly gets dispersible tablet.Oral, three times on the one, each 2.
Embodiments of the invention 5: the preparation of dispersible tablet
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.06, gets Cortex Cinnamomi extract 100g, and is standby; Get low-substituted hydroxypropyl cellulose 22.5g, carboxymethyl starch sodium 18g, mixing, get 3/5 with metformin hydrochloride 90g, glipizide 2g, Cortex Cinnamomi extract 100g, mix homogeneously is made binding agent with 15% starch slurry, 40 order system material, granulate, the mixed powder, the 2.2g magnesium stearate that remain 2/5 low-substituted hydroxypropyl cellulose and carboxymethyl starch sodium are added in the granule that makes, mixing, tabletting promptly gets dispersible tablet.
Embodiments of the invention 6: the preparation of dispersible tablet
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.06, gets Cortex Cinnamomi extract 100g, and is standby; Get low-substituted hydroxypropyl cellulose 37.6g, carboxymethyl starch sodium 28.2g, mixing, get 3/5 with metformin hydrochloride 188g, glipizide 4g, Cortex Cinnamomi extract 100g, mix homogeneously is made binding agent with 10% starch slurry, 40 order system material, granulate, the mixed powder, the 3.2g magnesium stearate that remain 2/5 low-substituted hydroxypropyl cellulose and carboxymethyl starch sodium are added in the granule that makes, mixing, tabletting promptly gets dispersible tablet.
Embodiments of the invention 7: the preparation of pellet
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.06, gets Cortex Cinnamomi extract 150g, and is standby; Get metformin hydrochloride 125g, glipizide 2.5g, starch 25g, add Cortex Cinnamomi extract 150g, mixing, with 20% ethanol and 1.2% soybean oil system soft material, the soft material that makes micropill mechanism ball, wet feed pushed the 0.8mm sieve aperture, the wet grain of strip cuts off round as a ball, and 50-60 ℃ of drying and moulding crossed 16 mesh sieves and selected ball, wet-milling granulation molding, mould placed add the great achievement ball in the coating pan, medicated powder: water is 1:1.2, the coating pan rotating speed is 35r/min, capping selects ball, promptly gets pellet.
Embodiments of the invention 8: the preparation of pellet
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.06, gets Cortex Cinnamomi extract 150g, and is standby; Get metformin hydrochloride 125g, glipizide 2.5g, starch 37.5g, add Cortex Cinnamomi extract 150g, mixing, with 30% ethanol and 1.5% soybean oil system soft material, the soft material that makes micropill mechanism ball, wet feed pushed the 0.8mm sieve aperture, the wet grain of strip cuts off round as a ball, and 50-60 ℃ of drying and moulding crossed 20 mesh sieves and selected ball, wet-milling granulation molding, mould placed add the great achievement ball in the coating pan, medicated powder: water is 1:1.5, the coating pan rotating speed is 40r/min, capping selects ball, promptly gets pellet.
Embodiments of the invention 9: the preparation of pellet
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.06, gets Cortex Cinnamomi extract 150g, and is standby; Get metformin hydrochloride 125g, glipizide 2.5g, starch 31.25g, add Cortex Cinnamomi extract 150g, mixing, with 20% ethanol and 1.35% soybean oil system soft material, the soft material that makes micropill mechanism ball, wet feed pushed the 0.8mm sieve aperture, the wet grain of strip cuts off round as a ball, and 50-60 ℃ of drying and moulding crossed 18 mesh sieves and selected ball, wet-milling granulation molding, mould placed add the great achievement ball in the coating pan, medicated powder: water is 1:1.35, the coating pan rotating speed is 35r/min, capping selects ball, promptly gets pellet.
Embodiments of the invention 10: the preparation of soft capsule
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.05, gets Cortex Cinnamomi extract 200g, and is standby; Get metformin hydrochloride 160g, glipizide 3g, PEG400 24g, sorbitol 32g, add Cortex Cinnamomi extract 200g, mixing; Press medication amount: substrate amount=1:1.5 adds soybean oil, mixing; The prescription of rubber is a gelatin: glycerol: water: titanium dioxide=100:45:100:2, batchingization adhesive tape part is: weigh batching, in the inputization glue jar, merceration is warming up to 65 ± 5 ℃ gradually after 60 minutes, stirred 4 hours and simultaneously evacuation remove bubble, treat evenly back blowing of sizing material, incapsulate after the filtration in the sizing material bucket of machine; The debugging pellet press, 65 ± 5 ℃ of gelatin box temperature controls, mould rotating speed 3.0 is rolled in 45 ± 5 ℃ of sprinkler body temperature controls, rubber thickness 0.7-0.8mm, indoor temperature 18-25 ℃, relative humidity is less than 40%, pelleting; The dry typing drying of rolling that adopts combined with two steps of tray dried, dry 3 hours of the typing of rolling, and 25 ± 5 ℃ of baking temperatures, dry relative humidity 48 hours drying times, promptly get soft capsule less than 40%.Oral, three times on the one, each 2.
Embodiments of the invention 11: the preparation of soft capsule
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.05, gets Cortex Cinnamomi extract 200g, and is standby; Get metformin hydrochloride 160g, glipizide 3g, PEG400 8g, sorbitol 16g, add Cortex Cinnamomi extract 200g, mixing; Press medication amount: substrate amount=1:1.2 adds soybean oil, mixing; The prescription of rubber is a gelatin: glycerol: water: titanium dioxide=100:45:100:2, batchingization adhesive tape part is: weigh batching, in the inputization glue jar, merceration is warming up to 65 ± 5 ℃ gradually after 60 minutes, stirred 2 hours and simultaneously evacuation remove bubble, treat evenly back blowing of sizing material, incapsulate after the filtration in the sizing material bucket of machine; The debugging pellet press, 65 ± 5 ℃ of gelatin box temperature controls, mould rotating speed 1.0 is rolled in 45 ± 5 ℃ of sprinkler body temperature controls, rubber thickness 0.7-0.8mm, indoor temperature 18-25 ℃, relative humidity is less than 40%, pelleting; The dry typing drying of rolling that adopts combined with two steps of tray dried, dry 1 hour of the typing of rolling, and 25 ± 5 ℃ of baking temperatures, dry relative humidity 24 hours drying times, promptly get soft capsule less than 40%.
Embodiments of the invention 12: the preparation of soft capsule
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.05, gets Cortex Cinnamomi extract 150g, and is standby; Get metformin hydrochloride 75g, glipizide 2g, PEG400 7.5g, sorbitol 15g, add Cortex Cinnamomi extract 150g, mixing; Press medication amount: substrate amount=1:1.4 adds soybean oil, mixing; The prescription of rubber is a gelatin: glycerol: water: titanium dioxide=100:45:100:2, batchingization adhesive tape part is: weigh batching, in the inputization glue jar, merceration is warming up to 65 ± 5 ℃ gradually after 60 minutes, stirred 3 hours and simultaneously evacuation remove bubble, treat evenly back blowing of sizing material, incapsulate after the filtration in the sizing material bucket of machine; The debugging pellet press, 65 ± 5 ℃ of gelatin box temperature controls, mould rotating speed 2.0 is rolled in 45 ± 5 ℃ of sprinkler body temperature controls, rubber thickness 0.7-0.8mm, indoor temperature 18-25 ℃, relative humidity is less than 40%, pelleting; The dry typing drying of rolling that adopts combined with two steps of tray dried, dry 2 hours of the typing of rolling, and 25 ± 5 ℃ of baking temperatures, dry relative humidity 30 hours drying times, promptly get soft capsule less than 40%.
Embodiments of the invention 13: the preparation of drop pill
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.06, gets Cortex Cinnamomi extract 225g, and is standby; Get metformin hydrochloride 188g, glipizide 4g, Cortex Cinnamomi extract 225g, mixing; Taking polyethylene glycol 4000 894g, polyoxyethylene monostearate S-40 447g fuse in the water-bath, stir evenly, and drip to become ball in dimethicone, drip apart from 6cm, and drip footpath 2.5mm/2mm mixes 85 ℃ of ointment temperature, and liquid coolant height 75cm promptly gets drop pill.
Embodiments of the invention 14: the preparation of drop pill
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.06, gets Cortex Cinnamomi extract 225g, and is standby; Get metformin hydrochloride 62g, glipizide 1g, Cortex Cinnamomi extract 225g, mixing; Taking polyethylene glycol 4000 576g, polyoxyethylene monostearate S-40 288g with said mixture, fuse in the water-bath, stir evenly, drip and in dimethicone, to become ball, drip apart from 4cm drip footpath 2.5mm/2mm, mix 75 ℃ of ointment temperature, liquid coolant height 65cm promptly gets drop pill.
Embodiments of the invention 15: the preparation of drop pill
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.06, gets Cortex Cinnamomi extract 75g, and is standby; Get metformin hydrochloride 188g, glipizide 4g, Cortex Cinnamomi extract 75g, mixing; Taking polyethylene glycol 4000 534g, polyoxyethylene monostearate S-40
267g with said mixture, fuses in the water-bath, stirs evenly, and drips to become ball in dimethicone, drips apart from 5cm, and drip footpath 2.5mm/2mm mixes 80 ℃ of ointment temperature, and liquid coolant height 70cm promptly gets drop pill.
Embodiments of the invention 16: the preparation of tablet
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.04, gets Cortex Cinnamomi extract 75g, and is standby; Get metformin hydrochloride 160g, glipizide 2g, starch 24g, carboxymethyl starch sodium 16g, add Cortex Cinnamomi extract 75g, mixing is used 10% alcohol granulation, drying, granulate adds 1% carboxymethyl starch sodium 2.8g, 0.5% magnesium stearate 1.4g, mixing, tabletting, coating promptly gets tablet.Oral, three times on the one, each 2.
Embodiments of the invention 17: the preparation of tablet
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.04, gets Cortex Cinnamomi extract 75g, and is standby; Get metformin hydrochloride 90g, glipizide 3g, starch 22.5g, carboxymethyl starch sodium 18g, add Cortex Cinnamomi extract 75g, mixing is used 50% alcohol granulation, drying, granulate adds 5% carboxymethyl starch sodium 10.4g, 1% magnesium stearate 2.1g, mixing, tabletting, coating promptly gets tablet.
Embodiments of the invention 18: the preparation of tablet
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.04, gets Cortex Cinnamomi extract 150g, and is standby; Get metformin hydrochloride 90g, glipizide 2.5g, starch 18g, carboxymethyl starch sodium 13.5g, add Cortex Cinnamomi extract 150g, mixing is used 30% alcohol granulation, dry, granulate adds 3% carboxymethyl starch sodium 8.2g, 0.8% magnesium stearate 2.2g, mixing, tabletting, coating promptly gets tablet.
Embodiments of the invention 19: the preparation of oral liquid formulations
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.05, gets Cortex Cinnamomi extract 100g, and is standby; Get metformin hydrochloride 160g, glipizide 2g, add Cortex Cinnamomi extract 100g, mixing adds distilled water, 2% aspartame 5.24g, and sterilization promptly gets oral liquid.
Embodiments of the invention 20: the preparation of oral liquid formulations
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.05, gets Cortex Cinnamomi extract 100g, and is standby; Get metformin hydrochloride 160g, glipizide 2g, add Cortex Cinnamomi extract 100g, mixing adds distilled water, 5% aspartame 13.1g, and sterilization promptly gets oral liquid.
Embodiments of the invention 21: the preparation of oral liquid formulations
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.05, gets Cortex Cinnamomi extract 75g, and is standby; Get metformin hydrochloride 125g, glipizide 2g, add Cortex Cinnamomi extract 75g, mixing adds distilled water, 3% aspartame 6.1g, and sterilization promptly gets oral liquid.
Embodiments of the invention 22: the preparation of powder
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.05, gets Cortex Cinnamomi extract 75g, and is standby; Get metformin hydrochloride 62g, glipizide 3g, starch 12.4g, add Cortex Cinnamomi extract 75g, mixing, drying and crushing is sieved, divided dose, packing promptly gets powder.
Embodiments of the invention 23: the preparation of powder
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.05, gets Cortex Cinnamomi extract 75g, and is standby; Get metformin hydrochloride 62g, glipizide 3g, starch 18.6g, add Cortex Cinnamomi extract 75g, mixing, drying and crushing is sieved, divided dose, packing promptly gets powder.
Embodiments of the invention 24: the preparation of powder
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.05, gets Cortex Cinnamomi extract 225g, and is standby; Get metformin hydrochloride 160g, glipizide 1g, starch 40g, add Cortex Cinnamomi extract 225g, mixing, drying and crushing is sieved, divided dose, packing promptly gets powder.
Embodiments of the invention 25: the preparation of capsule
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.05, gets Cortex Cinnamomi extract 225g, and is standby; Get metformin hydrochloride 188g, glipizide 2.5g, add the starch of 28.2g, mix homogeneously is used 80% alcohol granulation, filling, promptly.
Embodiments of the invention 26: the preparation of capsule
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.05, gets Cortex Cinnamomi extract 225g, and is standby; Get metformin hydrochloride 188g, glipizide 2.5g, add the starch of 75.2g, mix homogeneously is used 80% alcohol granulation, filling, promptly.
Embodiments of the invention 27: the preparation of capsule
Get cinnamomic dry, leaf vapor distillation extraction method extraction 3 times, each 2 hours, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.05, gets Cortex Cinnamomi extract 200g, and is standby; Get metformin hydrochloride 62g, glipizide 3g, add the starch of 18.6g, mix homogeneously is used 80% alcohol granulation, filling, promptly.
Claims (12)
- [claim 1] a kind of compounding metformin glipidide for the treatment of type 2 diabetes mellitus, it is characterized in that: according to listed as parts by weight, it is with 75～225 parts of 62～188 parts of metformin hydrochloride, 1～4 part of glipizide and Cortex Cinnamomi extracts, and in addition right amount of auxiliary materials is made into: coated tablet, dispersible tablet, hard capsule, soft capsule, granule, powder, pellet, drop pill or oral liquid; Wherein Cortex Cinnamomi extract is such preparation: get cinnamomic dry branch, leaf vapor distillation extraction method extraction 2～4 times, and each 1～3 hour, merge volatile oil, when being 20 ℃, temperature measures relative density, and its relative density is 1.0～1.1, promptly.
- [claim 2] is according to the compounding metformin glipidide of the described treatment type 2 diabetes mellitus of claim 1, it is characterized in that: according to listed as parts by weight, it is with 100～200 parts of 90～160 parts of metformin hydrochloride, 2～3 parts of glipizide and Cortex Cinnamomi extracts, and in addition right amount of auxiliary materials is made into coated tablet, dispersible tablet, hard capsule, soft capsule, granule, powder, pellet, drop pill or oral liquid.
- [claim 3] is according to the compounding metformin glipidide of the described treatment type 2 diabetes mellitus of claim 1, it is characterized in that: according to listed as parts by weight, it is with 150 parts of 125 parts of metformin hydrochloride, 2.5 parts of glipizide and Cortex Cinnamomi extracts, and in addition right amount of auxiliary materials is made into coated tablet, dispersible tablet, hard capsule, soft capsule, granule, powder, pellet, drop pill or oral liquid.
- [claim 4] is according to the preparation method of the compounding metformin glipidide of any described treatment type 2 diabetes mellitus among the claim 1-3, it is characterized in that: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract, the starch that adds the 40%-60% of metformin hydrochloride weight, the dextrin of the 40%-60% of metformin hydrochloride weight, mixing, ethanol system wet granular with 10～30%, dry, granulate, packing promptly gets granule.
- [claim 5] is characterized in that according to the preparation method of the compounding metformin glipidide of any described treatment type 2 diabetes mellitus among the claim 1-3: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract, mixing; Other gets 15%～25% low-substituted hydroxypropyl cellulose of metformin hydrochloride weight, the carboxymethyl starch sodium of the 10%-20% of metformin hydrochloride weight, mixing, get 3/5 with the mixed powder mix homogeneously of metformin hydrochloride, glipizide and Cortex Cinnamomi extract, starch slurry with 5～15% is made binding agent, 40 order system material, granulate, mixed powder and 0.5～1% part of magnesium stearate of adding residue 2/5 low-substituted hydroxypropyl cellulose and carboxymethyl starch sodium are added in the granule that makes, mixing, tabletting promptly gets dispersible tablet.
- [claim 6] is according to the preparation method of the compounding metformin glipidide of any described treatment type 2 diabetes mellitus among the claim 1-3, it is characterized in that: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract, the starch that adds the 20%-30% of metformin hydrochloride weight, mixing, with 20～30% ethanol and 1.2～1.5% soybean oil system soft materials, the soft material that makes micropill mechanism ball, wet feed pushed the 0.8mm sieve aperture, the wet grain of strip cuts off round as a ball, 50～60 ℃ of drying and mouldings are crossed 16～20 mesh sieves and are selected ball or spray drying, wet-milling granulation molding, mould placed add the great achievement ball in the coating pan, medicated powder: water is 1:1.2～1.5, and the coating pan rotating speed is 35～45r/min, capping, select ball, promptly get pellet.
- [claim 7] is according to the preparation method of the compounding metformin glipidide of any described treatment type 2 diabetes mellitus among the claim 1-3, it is characterized in that: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract, the PEG400 that adds the 5%-15% of metformin hydrochloride weight, the sorbitol of the 10%-20% of metformin hydrochloride weight, mixing; Press medication amount: substrate amount=1:1.2～1.5 add soybean oils, mixing; The prescription of rubber is a gelatin: glycerol: water: titanium dioxide=100:45:100:2, batchingization adhesive tape part is: weigh batching, in the inputization glue jar, merceration is warming up to 65 ± 5 ℃ gradually after 30～60 minutes, stirred 2～4 hours and simultaneously evacuation remove bubble, treat evenly back blowing of sizing material, incapsulate after the filtration in the sizing material bucket of machine; The debugging pellet press, 65 ± 5 ℃ of gelatin box temperature controls, mould rotating speed 1.0～3.0 is rolled in 45 ± 5 ℃ of sprinkler body temperature controls, rubber thickness 0.7～0.8mm, 18～25 ℃ of indoor temperatures, relative humidity is less than 40%, pelleting; The dry typing drying of rolling that adopts combined with two steps of tray dried, dry 1～3 hour of the typing of rolling, and 25 ± 5 ℃ of baking temperatures, dry relative humidity should be lower than 40%, and promptly got soft capsule at 24～48 hours drying time.
- [claim 8] is characterized in that according to the preparation method of the compounding metformin glipidide of any described treatment type 2 diabetes mellitus among the claim 1-3: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract mixing; Get the said mixture portion, two parts of Macrogol 4000s, polyoxyethylene monostearate S-40 portion, mix homogeneously, dissolve in the water-bath, stir evenly, drip and in dimethicone, to become ball, drip apart from 3～7cm, drip footpath 2.5mm/2mm, mix 80 ± 5 ℃ of ointment temperature, liquid coolant height 70 ± 5cm promptly gets drop pill.
- [claim 9] is according to the preparation method of the compounding metformin glipidide of any described treatment type 2 diabetes mellitus among the claim 1-3, it is characterized in that: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract, the starch that adds the 15%-25% of metformin hydrochloride weight, the carboxymethyl starch sodium of the 10%-20% of metformin hydrochloride weight, mixing, with 10～50% alcohol granulations, dry, granulate adds 1～5% part carboxymethyl starch sodium, 0.5～1% part magnesium stearate, mixing, tabletting, coating promptly gets coated tablet.
- [claim 10] is according to the preparation method of the compounding metformin glipidide of any described treatment type 2 diabetes mellitus among the claim 1-3, it is characterized in that: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract, mixing, add distilled water, 2～5% aspartame, sterilization promptly gets oral liquid.
- [claim 11] is according to the preparation method of the two 17 guanidine glipizide preparations of compound recipe diformazan of any described treatment type 2 diabetes mellitus among the claim 1-3, it is characterized in that: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract, the starch that adds the 20%-30% of metformin hydrochloride weight, mixing, drying and crushing is sieved, divided dose, packing promptly gets powder.
- [claim 12] is according to the preparation method of the compounding metformin glipidide of any described treatment type 2 diabetes mellitus among the claim 1-3, it is characterized in that: get metformin hydrochloride, glipizide, Cortex Cinnamomi extract, mixing, 15%～40% the starch that adds metformin hydrochloride weight, mix homogeneously, use 80% alcohol granulation, filling promptly gets hard capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005102005848A CN100496496C (en) | 2005-10-08 | 2005-10-08 | Compound metformin glipidide preparation for treating diabetes type II, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005102005848A CN100496496C (en) | 2005-10-08 | 2005-10-08 | Compound metformin glipidide preparation for treating diabetes type II, and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1785188A CN1785188A (en) | 2006-06-14 |
| CN100496496C true CN100496496C (en) | 2009-06-10 |
Family
ID=36782856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005102005848A Expired - Fee Related CN100496496C (en) | 2005-10-08 | 2005-10-08 | Compound metformin glipidide preparation for treating diabetes type II, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100496496C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101658487B (en) * | 2008-08-28 | 2011-10-05 | 北京天川军威医药技术开发有限公司 | Glimepiride aqueous solution administration system and preparation method thereof |
| CN102274285B (en) * | 2011-07-20 | 2014-07-02 | 天津市聚星康华医药科技有限公司 | Pharmaceutical composition for treating type 2 diabetes and complications thereof |
| CN102266388B (en) * | 2011-07-20 | 2014-08-27 | 天津市聚星康华医药科技有限公司 | Pharmaceutical composition for preventing and treating type 2 diabetes and complication thereof |
| CN102274514B (en) * | 2011-07-20 | 2014-08-27 | 天津市聚星康华医药科技有限公司 | Medicinal composition for preventing and treating type-II diabetes and complications thereof |
-
2005
- 2005-10-08 CN CNB2005102005848A patent/CN100496496C/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 肉桂研究进展. 陈旭，雍克岚.食品研究与开发，第24卷第5期. 2003 |
| 肉桂研究进展. 陈旭，雍克岚.食品研究与开发，第24卷第5期. 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1785188A (en) | 2006-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006098604A1 (en) | Pharmaceutical composition for preventing and treating diabetes or glucose control abnormality comprising ginsenosides | |
| CN103070864A (en) | Repaglinide and metformin hydrochloride medicinal composition and its preparation method | |
| CN100496496C (en) | Compound metformin glipidide preparation for treating diabetes type II, and its preparation method | |
| CN101843617A (en) | Slow release preparation of compound Repaglinide-metformin hydrochloride | |
| CN1768800A (en) | Chinese medicinal formulation for treating blennorrhagia and urinary system infection, and preparation method thereof | |
| CN1813984B (en) | Chinese medicine preparation for treating liver disease and preparing method | |
| CN1772234B (en) | Chinese medicine preparation for treating women's disease and its preparation method | |
| CN106551915A (en) | Enteric-coated composition and preparation method thereof | |
| CN1768794B (en) | Chinese medicinal preparation for treating respiratory diseases and its preparing process | |
| CN101491605A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN100374132C (en) | Compound Chinese and Western medicine prepn for treating women's climacteric syndrome and its prepn | |
| CN100490808C (en) | Gliquilone slow-releasing preparation | |
| CN103110601B (en) | Gliclazide gastric floating tablet and preparation method thereof | |
| CN100500178C (en) | Chinese medicine preparation for treating gynecopathy and its preparation method | |
| CN100512866C (en) | Sanjin pharmaceutical preparation for treating urinary system diseases and process for preparing the same | |
| CN1813937B (en) | Compound formulation for treating hyperlipidemia and its preparing method | |
| CN1813886B (en) | Chinese medicine formulation for activating blood flow and removing blood stasis and stopping pain, and its preparing method | |
| CN101129532B (en) | Traditional Chinese medicine dispersible tablet for relieving cough and method of preparing the same | |
| CN1823961B (en) | Compound Chinese medicine for treating cough and panting, acute bronchitis caused by common cold and its preparation method | |
| CN1813895B (en) | Chinese medicine formulation of lunar caustic for activating blood flow and removing blood stasis, and stopping pain, and its preparing method | |
| CN1771940A (en) | Ulcer treating Western medicine prepn and its prepn process | |
| Kumari et al. | Formulation and Evaluation Fast Dissolving Tablet of Hibiscusrosa-sinensis Leaf Mucilage as Superdisintegrant | |
| CN1331461C (en) | Chinese medicine preparation for treating gynecopathy and its preparation method | |
| CN103432082A (en) | Glucosamine composition and preparation method thereof | |
| CN1772055A (en) | Hyperlipemia treating Chinese medicine prepn and its prepn process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHENQI PHAMACEUTICAL CO LTD, GUIZHOU Free format text: FORMER OWNER: GUIZHOU SHENQI GROUP HOLDING CO., LTD. Effective date: 20120327 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20120327 Address after: 550004 Guizhou Province, Guiyang city Beijing Road No. 1 Patentee after: GUIZHOU SHENQI PHARMACEUTICAL Co.,Ltd. Address before: 550004 Guizhou Province, Guiyang city Beijing Road No. 1 Patentee before: GUIZHOU MAOJKA GROUP HOLDING Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee |
Owner name: GUIZHOU SHENQI PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHENQI PHAMACEUTICAL CO LTD, GUIZHOU |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 550004 Guizhou Province, Guiyang city Beijing Road No. 1 Patentee after: GUIZHOU SHENQI PHARMACEUTICAL Co.,Ltd. Address before: 550004 Guizhou Province, Guiyang city Beijing Road No. 1 Patentee before: GUIZHOU SHENQI PHARMACEUTICAL Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090610 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |